185 related articles for article (PubMed ID: 36712071)
1. Enkurin: A novel marker for myeloproliferative neoplasms from platelet, megakaryocyte, and whole blood specimens.
Mosale Seetharam S; Liu Y; Wu J; Fechter L; Murugesan K; Maecker H; Gotlib J; Zehnder J; Paulmurugan R; Krishnan A
bioRxiv; 2023 Jan; ():. PubMed ID: 36712071
[TBL] [Abstract][Full Text] [Related]
2. Enkurin: a novel marker for myeloproliferative neoplasms from platelet, megakaryocyte, and whole blood specimens.
Seetharam SM; Liu Y; Wu J; Fechter L; Murugesan K; Maecker H; Gotlib J; Zehnder J; Paulmurugan R; Krishnan A
Blood Adv; 2023 Sep; 7(18):5433-5445. PubMed ID: 37315179
[TBL] [Abstract][Full Text] [Related]
3. Age-related macular degeneration and myeloproliferative neoplasms - A common pathway.
Liisborg C
Acta Ophthalmol; 2022 Oct; 100 Suppl 271(Suppl 271):3-35. PubMed ID: 36200281
[TBL] [Abstract][Full Text] [Related]
4. Thrombopoietin-independent Megakaryocyte Differentiation of Hematopoietic Progenitor Cells from Patients with Myeloproliferative Neoplasms.
Thompson-Peach CAL; Foßelteder J; Reinisch A; Thomas D
Bio Protoc; 2023 Jan; 13(2):e4592. PubMed ID: 36789162
[TBL] [Abstract][Full Text] [Related]
5. In vitro megakaryocyte differentiation and proplatelet formation in Ph-negative classical myeloproliferative neoplasms: distinct patterns in the different clinical phenotypes.
Balduini A; Badalucco S; Pugliano MT; Baev D; De Silvestri A; Cattaneo M; Rosti V; Barosi G
PLoS One; 2011; 6(6):e21015. PubMed ID: 21698292
[TBL] [Abstract][Full Text] [Related]
6. Molecular Pathogenesis of Myeloproliferative Neoplasms.
Rolles B; Mullally A
Curr Hematol Malig Rep; 2022 Dec; 17(6):319-329. PubMed ID: 36336766
[TBL] [Abstract][Full Text] [Related]
7. Tyrosine 625 plays a key role and cooperates with tyrosine 630 in MPL W515L-induced signaling and myeloproliferative neoplasms.
Yu C; Yang Q; Chen Y; Wang D; Levine R; Crispino J; Wen Q; Huang Z
Cell Biosci; 2016; 6():34. PubMed ID: 27222706
[TBL] [Abstract][Full Text] [Related]
8. TLR4 and RAGE conversely mediate pro-inflammatory S100A8/9-mediated inhibition of proliferation-linked signaling in myeloproliferative neoplasms.
Kovačić M; Mitrović-Ajtić O; Beleslin-Čokić B; Djikić D; Subotički T; Diklić M; Leković D; Gotić M; Mossuz P; Čokić VP
Cell Oncol (Dordr); 2018 Oct; 41(5):541-553. PubMed ID: 29946821
[TBL] [Abstract][Full Text] [Related]
9. Anti-apoptotic pathways in bone marrow and megakaryocytes in myeloproliferative neoplasia.
Koopmans SM; Schouten HC; van Marion AM
Pathobiology; 2014; 81(2):60-8. PubMed ID: 24280934
[TBL] [Abstract][Full Text] [Related]
10. ENKUR acts as a tumor suppressor in lung adenocarcinoma cells through PI3K/Akt and MAPK/ERK signaling pathways.
Ma Q; Lu Y; Lin J; Gu Y
J Cancer; 2019; 10(17):3975-3984. PubMed ID: 31417642
[TBL] [Abstract][Full Text] [Related]
11. Lack of COL6/collagen VI causes megakaryocyte dysfunction by impairing autophagy and inducing apoptosis.
Abbonante V; Malara A; Chrisam M; Metti S; Soprano P; Semplicini C; Bello L; Bozzi V; Battiston M; Pecci A; Pegoraro E; De Marco L; Braghetta P; Bonaldo P; Balduini A
Autophagy; 2023 Mar; 19(3):984-999. PubMed ID: 35857791
[TBL] [Abstract][Full Text] [Related]
12. PEDF reduces malignant cells proliferation and inhibits the progression of myelofibrosis in myeloproliferative neoplasms.
Li Y; Gao H; Dong H; Wang W; Xu Z; Wang G; Liu Y; Wang H; Ju W; Qiao J; Xu K; Fu C; Zeng L
Biochem Pharmacol; 2022 May; 199():115013. PubMed ID: 35318038
[TBL] [Abstract][Full Text] [Related]
13. Activation of JAK/STAT Signaling in Megakaryocytes Sustains Myeloproliferation
Woods B; Chen W; Chiu S; Marinaccio C; Fu C; Gu L; Bulic M; Yang Q; Zouak A; Jia S; Suraneni PK; Xu K; Levine RL; Crispino JD; Wen QJ
Clin Cancer Res; 2019 Oct; 25(19):5901-5912. PubMed ID: 31217200
[TBL] [Abstract][Full Text] [Related]
14. JAK2-V617F and interferon-α induce megakaryocyte-biased stem cells characterized by decreased long-term functionality.
Rao TN; Hansen N; Stetka J; Luque Paz D; Kalmer M; Hilfiker J; Endele M; Ahmed N; Kubovcakova L; Rybarikova M; Hao-Shen H; Geier F; Beisel C; Dirnhofer S; Schroeder T; Brümmendorf TH; Wolf D; Koschmieder S; Skoda RC
Blood; 2021 Apr; 137(16):2139-2151. PubMed ID: 33667305
[TBL] [Abstract][Full Text] [Related]
15. CALR frameshift mutations in MPN patient-derived iPSCs accelerate maturation of megakaryocytes.
Olschok K; Han L; de Toledo MAS; Böhnke J; Graßhoff M; Costa IG; Theocharides A; Maurer A; Schüler HM; Buhl EM; Pannen K; Baumeister J; Kalmer M; Gupta S; Boor P; Gezer D; Brümmendorf TH; Zenke M; Chatain N; Koschmieder S
Stem Cell Reports; 2021 Nov; 16(11):2768-2783. PubMed ID: 34678208
[TBL] [Abstract][Full Text] [Related]
16. [Clinical impact of gene mutations on myeloproliferative neoplasms in Japan].
Morishita S
Rinsho Ketsueki; 2021; 62(8):1060-1069. PubMed ID: 34497192
[TBL] [Abstract][Full Text] [Related]
17. JAK2-V617F is a negative regulation factor of SHIP1 protein and thus influences the AKT signaling pathway in patients with Myeloproliferative neoplasm (MPN).
Glück M; Dally L; Jücker M; Ehm P
Int J Biochem Cell Biol; 2022 Aug; 149():106229. PubMed ID: 35609769
[TBL] [Abstract][Full Text] [Related]
18. Increased Dkk3 protein expression in platelets and megakaryocytes of patients with myeloproliferative neoplasms.
Medinger M; Tzankov A; Kern J; Pircher A; Hermann M; Ott HW; Gastl G; Untergasser G; Gunsilius E
Thromb Haemost; 2011 Jan; 105(1):72-80. PubMed ID: 20978717
[TBL] [Abstract][Full Text] [Related]
19. ENKUR expression induced by chemically synthesized cinobufotalin suppresses malignant activities of hepatocellular carcinoma by modulating β-catenin/c-Jun/MYH9/USP7/c-Myc axis.
Hou R; Li Y; Luo X; Zhang W; Yang H; Zhang Y; Liu J; Liu S; Han S; Liu C; Huang Y; Liu Z; Li A; Fang W
Int J Biol Sci; 2022; 18(6):2553-2567. PubMed ID: 35414777
[TBL] [Abstract][Full Text] [Related]
20. Recent advances in understanding myelofibrosis and essential thrombocythemia.
Vainchenker W; Constantinescu SN; Plo I
F1000Res; 2016; 5():. PubMed ID: 27134742
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
